{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:44:53Z","timestamp":1789767893540,"version":"4.0.1"},"reference-count":116,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp;D Program of China","award":["2018YFA0108403"],"award-info":[{"award-number":["2018YFA0108403"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>There has been over half a century since the discovery of hepatitis B virus (HBV) to now, but approximately 300 million patients with chronic hepatitis B (CHB) still live in the world, resulting in about one million deaths every year. Although currently approved antivirals (e.g., nucleoside analogues) are effective at reducing HBV replication, they have almost no impact on the existing HBV covalently closed circular DNA (cccDNA) reservoir. HBV cccDNA is a critical obstacle to the complete elimination of the virus via antiviral therapy. The true cure of HBV infection requires the eradication of viral cccDNA from HBV-infected cells; thus, the development of new agents directly or indirectly targeting HBV cccDNA is urgently needed due to the limitations of current available drugs against HBV infection. In this regard, it is the major focus of current anti-HBV research worldwide via different mechanisms to either inactivate\/inhibit (functional cure) or eliminate (complete cure) HBV cccDNA. Therefore, this review discussed and summarized recent advances and challenges in efforts to inactivate\/silence or eliminate viral cccDNA using anti-HBV agents from different sources, such as small molecules (including epigenetic drugs) and polypeptides\/proteins, and siRNA or gene-editing approaches targeting\/attenuating HBV cccDNA via different mechanisms, as well as future directions that may be considered in efforts to truly cure chronic HBV infection. In conclusion, no breakthrough has been made yet in attenuating HBV cccDNA, although a number of candidates have advanced into the phase of clinical trials. Furthermore, the overwhelming majority of the candidates function to indirectly target HBV cccDNA. No outstanding candidate directly targets HBV cccDNA. Relatively speaking, CCC_R08 and nitazoxanide may be some of the most promising agents to clear HBV infection in small molecule compounds. Additionally, CRISPR-Cas9 systems can directly target HBV cccDNA for decay and demonstrate significant anti-HBV activity. Consequently, gene-editing approaches targeting HBV cccDNA may be one of the most promising means to achieve the core goal of anti-HBV therapeutic strategies. In short, more basic studies on HBV infection need to be carried out to overcome these challenges.<\/jats:p>","DOI":"10.3390\/v15122315","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:33:56Z","timestamp":1701056036000},"page":"2315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation\/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA"],"prefix":"10.3390","volume":"15","author":[{"given":"An-Qi","family":"Zhuang","sequence":"first","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Mei","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hang","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0042-6822(84)90231-9","article-title":"Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver","volume":"137","author":"Miller","year":"1984","journal-title":"Virology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4065\/82.8.967","article-title":"Natural history of hepatitis B virus infection: An update for clinicians","volume":"82","author":"Pungpapong","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","unstructured":"Hepatitis B Foundation (2023, November 12). What Is Hepatitis B?. Available online: https:\/\/www.hepb.org\/what-is-hepatitis-b\/what-is-hepb\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S1473-3099(15)00436-3","article-title":"New therapeutic agents for chronic hepatitis B","volume":"16","author":"Brahmania","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, L., Cheng, S.T., Qin, Y.P., He, X., Li, F., Wu, D.Q., Ren, F., Yu, H.B., and Liu, J. (2022). Rapamycin inhibits hepatitis B virus covalently closed circular DNA transcription by enhancing the ubiquitination of HBx. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.850087"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Takeuchi, F., Ikeda, S., Tsukamoto, Y., Iwasawa, Y., Qihao, C., Otakaki, Y., Ryota, O., Yao, W.L., Narita, R., and Makoto, H. (2019). Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212233"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","article-title":"Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gilmore, S.A., Tam, D., Cheung, T.L., Snyder, C., Farand, J., Dick, R., Matles, M., Feng, J.Y., Ramirez, R., and Li, L. (2022). Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus. PLoS ONE, 17.","DOI":"10.1101\/2022.06.27.497732"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31855-X","article-title":"Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model","volume":"66","author":"Gilmore","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wu, J., Li, X., Guo, X., Cheng, Z., Meng, J., Cheng, W., and Lin, W. (2020). Briarane-type diterpenoids from a gorgonian coral Ellisella sp. With anti-HBV activities. Bioorg. Chem., 105.","DOI":"10.1016\/j.bioorg.2020.104423"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, X., Liu, H., Chqeng, W., Wang, J., Zhang, H., Lu, F., Chen, X., and Lin, W. (2020). Junceellolide B, a novel inhibitor of Hepatitis B virus. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115603"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.jmedchem.1c02215","article-title":"Discovery of novel cccDNA reducers toward the cure of hepatitis B virus infection","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3748\/wjg.v17.i11.1507","article-title":"Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication\u2014Inducible cell line","volume":"17","author":"He","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.09.009","article-title":"(-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes","volume":"111","author":"Huang","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1770","DOI":"10.1038\/cddis.2015.136","article-title":"Epigallocatechin-3-gallate opposes HBV-induced incomplete autophagy by enhancing lysosomal acidification, which is unfavorable for HBV replication","volume":"6","author":"Zhong","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nakanishi, A., Okumura, H., Hashita, T., Yamashita, A., Nishimura, Y., Watanabe, C., Kamimura, S., Hayashi, S., Murakami, S., and Ito, K. (2022). Ivermectin inhibits HBV entry into the nucleus by suppressing KPNA2. Viruses, 14.","DOI":"10.3390\/v14112468"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41598-019-56842-9","article-title":"Development of a novel anti-hepatitis B virus agent via Sp1","volume":"10","author":"Hayakawa","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00214","DOI":"10.1128\/AAC.00214-17","article-title":"An Effective antiviral approach targeting hepatitis B virus with NJK14047, a novel and selective biphenyl amide p38 mitogen-activated protein kinase inhibitor","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"356806","DOI":"10.1155\/2012\/356806","article-title":"Anti-hepatitis B virus effect and possible mechanism of action of 3,4-O-dicaffeoylquinic Acid in vitro and in vivo","volume":"2012","author":"Wu","year":"2012","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jep.2012.09.003","article-title":"Hepatoprotective and antiviral properties of isochlorogenic acid A from Laggera alata against hepatitis B virus infection","volume":"144","author":"Hao","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105485","DOI":"10.1016\/j.antiviral.2022.105485","article-title":"Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action","volume":"209","author":"Yan","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"837115","DOI":"10.3389\/fphar.2022.837115","article-title":"Pimobendan inhibits HBV transcription and replication by suppressing HBV promoters activity","volume":"13","author":"Yuan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e01463-20","DOI":"10.1128\/AAC.01463-20","article-title":"Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731","volume":"64","author":"Huang","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.aohep.2019.12.005","article-title":"Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR","volume":"19","author":"Bao","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-08-0836","article-title":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","volume":"8","author":"Byth","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00465-18","DOI":"10.1128\/AAC.00465-18","article-title":"Identification of retinoic acid receptor agonists as potent hepatitis B virus inhibitors via a drug repurposing screen","volume":"62","author":"Li","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Murai, K., Shirasaki, T., Honda, M., Shimizu, R., Shimakami, T., Nakasho, S., Shirasaki, N., Okada, H., Sakai, Y., and Yamashita, T. (2018). Peretinoin, an acyclic retinoid, inhibits hepatitis B virus replication by suppressing sphingosine metabolic pathway in vitro. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020108"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.3748\/wjg.v23.i34.6252","article-title":"Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation","volume":"23","author":"Wei","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2016.08.026","article-title":"Identification of tandardized tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA","volume":"134","author":"Liu","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bcp.2016.01.003","article-title":"Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein","volume":"103","author":"Liu","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","article-title":"Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity","volume":"120","author":"Wang","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jcmm.16137","article-title":"Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1\u03b1-C\/EBP\u03b1-HNF4\u03b1 axis","volume":"25","author":"Xie","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100551","DOI":"10.1016\/j.jhepr.2022.100551","article-title":"Dual role of neddylation in transcription of hepatitis B virus RNAs from cccDNA and production of viral surface antigen","volume":"4","author":"Qu","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11033-021-06886-w","article-title":"Blocking neddylation elicits antiviral effect against hepatitis B virus replication","volume":"49","author":"Abounouh","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1128\/AAC.01460-21","article-title":"Efficient inhibition of hepatitis B virus (HBV) replication and cccDNA formation by HBV ribonuclease H inhibitors during infection","volume":"65","author":"Chauhan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20402066221138705","DOI":"10.1177\/20402066221138705","article-title":"Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens","volume":"30","author":"Gish","year":"2022","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/acs.jmedchem.7b00083","article-title":"Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors","volume":"60","author":"Qiu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e01440-19","DOI":"10.1128\/AAC.01440-19","article-title":"A new role for capsid assembly modulators to target mature hepatitis B virus capsids and prevent virus infection","volume":"64","author":"Ko","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hep.30514","article-title":"Direct Inhibition of hepatitis B e antigen by core protein allosteric modulator","volume":"70","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.08.012","article-title":"Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039","volume":"123","author":"Okamoto","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/1078-0432.CCR-17-3119","article-title":"CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has a therapeutic effect on HPV-induced neoplasia","volume":"24","author":"Ajiro","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sakamoto, T., Ajiro, M., Watanabe, A., Matsushima, S., Ueda, K., and Hagiwara, M. (2023). Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10540-y"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.antiviral.2016.08.008","article-title":"Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation","volume":"133","author":"Tanaka","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/hep4.2014","article-title":"Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy","volume":"6","author":"Murai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/S0168-8278(18)31226-1","article-title":"First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001","volume":"68","author":"Erken","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31853-6","article-title":"The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells","volume":"66","author":"Joly","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study","volume":"28","author":"Erken","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: A first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/hep4.1339","article-title":"A pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B","volume":"3","author":"Rossignol","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.13003","article-title":"Hepatitis B virus: New therapeutic perspectives","volume":"36","author":"Lin","year":"2016","journal-title":"Liver Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jvh.13490","article-title":"Clinical effects of NTCP-inhibitor myrcludex B","volume":"28","author":"Cheng","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105386","DOI":"10.1016\/j.antiviral.2022.105386","article-title":"Insights on the antiviral mechanisms of action of the TLR1\/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes","volume":"206","author":"Desmares","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.1254082","article-title":"Virology. Comment on \u201cSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA\u201d","volume":"344","author":"Chisari","year":"2014","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13148-020-00928-z","article-title":"IFN-\u03b1 confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA","volume":"12","author":"Yuan","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-\u03b1 to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathog."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00183-17","DOI":"10.1128\/AAC.00183-17","article-title":"Development of a novel site-specific pegylated interferon beta for antiviral therapy of chronic hepatitis B virus","volume":"61","author":"Tsuge","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/hepr.13450","article-title":"Molecular signature of hepatitis B virus regulation by interferon-\u03b3 in primary human hepatocytes","volume":"50","author":"Nosaka","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e49568","DOI":"10.15252\/embr.201949568","article-title":"Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20","volume":"22","author":"Stadler","year":"2021","journal-title":"EMBO Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1873-3468.12058","article-title":"TGF-\u03b2 triggers HBV cccDNA degradation through AID-dependent deamination","volume":"590","author":"Qiao","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e0126122","DOI":"10.1128\/jvi.01261-22","article-title":"Heat shock protein family a member 1 promotes intracellular amplification of hepatitis B virus covalently closed circular DNA","volume":"97","author":"Tang","year":"2023","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kim, J., Kwon, H., Kalsoom, F., Sajjad, M.A., Lee, H.W., Lim, J.H., Jung, J., Chwae, Y.J., Park, S., and Shin, H.J. (2022). Ca2+\/Calmodulin-dependent protein kinase II inhibits hepatitis B virus replication from cccDNA via AMPK activation and AKT\/mTOR suppression. Microorganisms, 10.","DOI":"10.3390\/microorganisms10030498"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3894816","DOI":"10.1155\/2016\/3894816","article-title":"Expression of interferon effector gene SART1 correlates with interferon treatment response against hepatitis B infection","volume":"2016","author":"Li","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jhep.2021.06.038","article-title":"Novel function of SART1 in HNF4\u03b1 transcriptional regulation contributes to its antiviral role during HBV infection","volume":"75","author":"Teng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, H., Sheng, C., Wang, S., Yang, L., Liang, Y., Huang, Y., Liu, H., Li, P., Yang, C., and Yang, X. (2017). Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front. Cell Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00091"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wang, D., Chen, L., Li, C., Long, Q., Yang, Q., Huang, A., and Tang, H. (2022). CRISPR\/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy. J. Nanobiotechnol., 20.","DOI":"10.1186\/s12951-021-01233-4"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.7150\/thno.18114","article-title":"The gRNA-miRNA-gRNA ternary cassette combining CRISPR\/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","article-title":"Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo","volume":"30","author":"Gorsuch","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1926233231202995","DOI":"10.1177\/01926233231202995","article-title":"Safety findings of dosing gene therapy vectors in NHP with pre-existing or treatment-emergent anti-capsid antibodies","volume":"51","author":"Chandra","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wooddell, C.I., Gehring, A.J., Yuen, M.F., and Given, B.D. (2021). RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies. Viruses, 13.","DOI":"10.3390\/v13040581"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12013-014-9847-1","article-title":"Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice","volume":"69","author":"Li","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"856463","DOI":"10.3389\/fimmu.2022.856463","article-title":"PreS\/2-21-guided siRNA nanoparticles target to inhibit hepatitis B virus infection and replication","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-020-80594-6","article-title":"Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection","volume":"11","author":"Kadelka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","article-title":"Eliminating cccDNA to cure hepatitis B virus infection","volume":"78","author":"Zoulim","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"809838","DOI":"10.3389\/fped.2021.809838","article-title":"Translational strategies to eliminate chronic hepatitis B in children: Prophylaxis and management in east asian countries","volume":"9","author":"Kang","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The role of cccDNA in HBV maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis B virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1134\/S0026893322060097","article-title":"Antiviral activity of CRISPR\/Cas9 ribonucleoprotein complexes on a hepatitis B virus model in vivo","volume":"56","author":"Kostyusheva","year":"2022","journal-title":"Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","article-title":"The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA","volume":"244","author":"Yang","year":"2018","journal-title":"Virus Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.jhepr.2021.100354","article-title":"Control of APOBEC3B induction and cccDNA decay by NF-\u03baB and miR-138-5p","volume":"3","author":"Riedl","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hep.20801","article-title":"APOBEC-mediated interference with hepadnavirus production","volume":"42","author":"Kann","year":"2005","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.omtn.2023.04.016","article-title":"Transient and tunable CRISPRa regulation of APOBEC\/AID genes for targeting hepatitis B virus","volume":"32","author":"Kostyushev","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(17)30838-3","article-title":"In vivo pharmacodynamics of GS-5801, a liver targeted prodrug of a lysine demethylase 5 inhibitor with antiviral activity against hepatitis B virus","volume":"66","author":"Gilmore","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_103","first-page":"61A","article-title":"Novel anti-HBV therapies using CRISPR\/cas9 targeting HBV genome strongly suppress HBV","volume":"72","author":"Kazuhiro","year":"2020","journal-title":"Hepatology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Brezgin, S., Kostyusheva, A., Bayurova, E., Gordeychuk, I., Isaguliants, M., Goptar, I., Nikiforova, A., Smirnov, V., Volchkova, E., and Glebe, D. (2019). Replenishment of hepatitis B virus cccDNA pool is restricted by baseline expression of host restriction factors in vitro. Microorganisms, 7.","DOI":"10.3390\/microorganisms7110533"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Mueller","year":"2016","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","article-title":"Hepatitis B virus X protein promotes degradation of SMC5\/6 to enhance HBV replication","volume":"16","author":"Murphy","year":"2016","journal-title":"Cell Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gutjnl-2021-324144","article-title":"Silencing HBV transcription with SMC5\/6: Has a path been found?","volume":"71","author":"Tavis","year":"2022","journal-title":"Gut"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.jhepr.2023.100849","article-title":"JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication","volume":"5","author":"Kong","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2174\/1389450120666190729115646","article-title":"Potential drug targets against hepatitis B virus based on both virus and host factors","volume":"20","author":"Zhang","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.29133","article-title":"PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e2103135","DOI":"10.1002\/advs.202103135","article-title":"LINC01431 promotes histone H4R3 methylation to impede HBV covalently closed circular DNA transcription by stabilizing PRMT1","volume":"9","author":"Sun","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","article-title":"Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9","volume":"31","author":"Kostyushev","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/cid\/ciw044","article-title":"Eradication strategies for chronic hepatitis B infection","volume":"62","author":"Wilson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.tim.2016.05.006","article-title":"Control and eradication strategies of hepatitis B virus","volume":"24","author":"Shih","year":"2016","journal-title":"Trends Microbiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:30:20Z","timestamp":1760131820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":116,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122315"],"URL":"https:\/\/doi.org\/10.3390\/v15122315","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]}}}